Literature DB >> 21714795

Nephrotoxicity, including acquired Fanconi's syndrome, caused by adefovir dipivoxil - is there a safe dose?

S-T Law1, K K Li, Y Y Ho.   

Abstract

WHAT IS KNOWN AND
OBJECTIVE: Adefovir dipivoxil (ADV) is an oral bioavailable prodrug of adefovir that possesses potent in vitro activity against hepadnaviruses, retroviruses and herpes viruses. ADV is excreted unchanged in the urine through glomerular filtration and tubular secretion and is known to be nephrotoxic at doses of 60mg daily and above. Thus, the long-term safety of ADV, particularly nephrotoxicity, is a major concern. Our objective is to comment on the nephrotoxcicity of low-dose (10mg daily) ADV through a case report. COMMENT: The clinical features of nephrotoxicity because of ADV are described. A case report of acquired Fanconi's syndrome in a chronic hepatitis B patient treated with ADV 10mg daily is used to illustrate several key aspects. WHAT IS NEW AND
CONCLUSION: Adefovir dipivoxil can be nephrotoxic at conventional dosage and therefore, patients treated with long-term ADV should have regular monitoring of renal function, and calcium and phosphate levels.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21714795     DOI: 10.1111/j.1365-2710.2011.01278.x

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  13 in total

1.  Adefovir-induced Fanconi syndrome: diagnostic pearls and perils of late or missed diagnosis.

Authors:  Samuel Shang Ming Lee; Timothy Peng Lim Quek; Cherng Jye Seow; Melvin Khee Shing Leow
Journal:  CEN Case Rep       Date:  2014-03-14

2.  Adefovir dipivoxil-induced Fanconi syndrome and its predictive factors: A study of 28 cases.

Authors:  Yong Lin; Fan Pan; Yingchao Wang; Ziqian Chen; Chun Lin; Lvfeng Yao; Xin Zhang; Rui Zhou; Chen Pan
Journal:  Oncol Lett       Date:  2016-11-17       Impact factor: 2.967

3.  Predictors of kidney tubular dysfunction induced by adefovir treatment for chronic hepatitis B.

Authors:  Motohiro Shimizu; Norihiro Furusyo; Hiroaki Ikezaki; Eiichi Ogawa; Takeo Hayashi; Takeshi Ihara; Yuji Harada; Kazuhiro Toyoda; Masayuki Murata; Jun Hayashi
Journal:  World J Gastroenterol       Date:  2015-02-21       Impact factor: 5.742

4.  Acquired hypophosphatemic osteomalacia is easily misdiagnosed or neglected by rheumatologists: A report of 9 cases.

Authors:  Ling Li; Shu-Xia Wang; Hong-Mei Wu; Dong-Lan Luo; Guang-Fu Dong; Yuan Feng; Xiao Zhang
Journal:  Exp Ther Med       Date:  2018-04-27       Impact factor: 2.447

5.  Renal dysfunction and hypophosphatemia during long-term lamivudine plus adefovir dipivoxil therapy in patients with chronic hepatitis B.

Authors:  Mio Tanaka; Fumitaka Suzuki; Yuya Seko; Tasuku Hara; Yusuke Kawamura; Hitomi Sezaki; Tetsuya Hosaka; Norio Akuta; Masahiro Kobayashi; Yoshiyuki Suzuki; Satoshi Saitoh; Yasuji Arase; Kenji Ikeda; Mariko Kobayashi; Hiromitsu Kumada
Journal:  J Gastroenterol       Date:  2013-03-26       Impact factor: 7.527

Review 6.  Current recommendations of managing HBV infection in preconception or pregnancy.

Authors:  James S Park; Calvin Pan
Journal:  Front Med       Date:  2014-05-29       Impact factor: 4.592

7.  Amidate prodrugs of 9-[2-(phosphonomethoxy)ethyl]adenine as inhibitors of adenylate cyclase toxin from Bordetella pertussis.

Authors:  Markéta Šmídková; Alexandra Dvoráková; Eva Tloust'ová; Michal Česnek; Zlatko Janeba; Helena Mertlíková-Kaiserová
Journal:  Antimicrob Agents Chemother       Date:  2013-10-21       Impact factor: 5.191

8.  Pathologic Femoral Neck Fracture Due to Fanconi Syndrome Induced by Adefovir Dipivoxil Therapy for Hepatitis B.

Authors:  Yoon-Suk Lee; Byung-Kook Kim; Ho-Jae Lee; Jinmyoung Dan
Journal:  Clin Orthop Surg       Date:  2016-05-10

9.  Nephrogenic hypophosphatemic osteomalacia during adefovir monotherapy for chronic hepatitis B monoinfection.

Authors:  Yaowen Xu; Pingyan Shen; Xiaoxia Pan; Nan Chen
Journal:  Clin Kidney J       Date:  2013-08

10.  Adefovir dipivoxil induced hypophosphatemic osteomalacia in chronic hepatitis B: a comparative study of Chinese and foreign case series.

Authors:  Nan Chen; Jian-Bo Zhang; Qiujie Zhang; Yun-Peng Zhao; Li-Yan Li; Li-Wei Liu; Fei Yu; Xin Yu; Tao Peng; Kuan-Xiao Tang
Journal:  BMC Pharmacol Toxicol       Date:  2018-05-16       Impact factor: 2.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.